Genmab

Genmab A/S Gears Up for Annual General Meeting and Stock Buyback, Eyes Late-Stage Assets

Genmab A/S announces Annual General Meeting date and buyback program, resulting in 12% stock jump. The Danish biotech company is actively seeking late-stage assets for co-commercialization.

Genmab A/S, a leading biotech company in Denmark, has scheduled its Annual General Meeting for March 13, 2024. The announcement comes as the company's stock, GMAB, surged by 7.25% and hit a pre-market high. Genmab has also ventured into co-commercialization and is on the lookout for more late-stage assets. The recent buyback program declaration by Genmab led to a 12% increase in stock value, marking a four-week high.